Oslo - Delayed Quote • NOK
Photocure ASA (PHO.OL)
At close: April 26 at 4:25 PM GMT+2
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in NOK.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Daniel Schneider | President & CEO | -- | -- | -- |
| Mr. Erik Dahl | Chief Financial Officer | -- | -- | 1957 |
| Mr. David Moskowitz | Head of Investor Relations | -- | -- | -- |
| Dr. Anders Neijber M.D. | Chief Medical Officer of Global Medical Affairs, Clinical Development and R&D | -- | -- | -- |
| Mr. Tolv Hillestad | Group Controller | -- | -- | -- |
Photocure ASA
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Description
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
Corporate Governance
Photocure ASA’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 4; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- May 23, 2013Ex-Dividend Date
Upcoming Events
May 15, 2024
Photocure ASA Earnings Call
Related Tickers
NEWBRY.ST Newbury Pharmaceuticals AB (publ)
3.4100
+2.71%
0512.HK Grand Pharmaceutical Group Limited
4.320
+1.41%
HLUN-A.CO H. Lundbeck A/S
28.15
+0.72%
NXS.AX Next Science Limited
0.3400
+7.94%
BIOG-B.ST BioGaia AB (publ)
115.20
+1.23%
HLUN-B.CO H. Lundbeck A/S
32.92
+1.11%
HROW Harrow, Inc.
10.53
+5.30%
CPH.TO Cipher Pharmaceuticals Inc.
8.50
0.00%
SIGA SIGA Technologies, Inc.
8.79
+1.74%
TEVA Teva Pharmaceutical Industries Limited
13.81
+4.23%